Email updates

Keep up to date with the latest news and content from BMC Medical Research Methodology and BioMed Central.

Open Access Highly Accessed Debate

The probability of cost-effectiveness

Anthony O'Hagan1* and John W Stevens2

Author Affiliations

1 Centre for Bayesian Statistics in Health Economics, University of Sheffield, Sheffield, UK

2 Clinical Sciences, AstraZeneca R&D Charnwood, Loughborough, UK

For all author emails, please log on.

BMC Medical Research Methodology 2002, 2:5  doi:10.1186/1471-2288-2-5

Published: 11 March 2002

Abstract

Background

The study of cost-effectiveness comparisons between competing medical interventions has led to a variety of proposals for quantifying cost-effectiveness. The differences between the various approaches can be subtle, and one purpose of this article is to clarify some important distinctions.

Discussion

We discuss alternative measures in the framework of individual, patient-level, incremental net benefits. In particular we examine the probability of cost-effectiveness for an individual, proposed by Willan.

Summary

We argue that this is a useful addition to the range of cost-effectiveness measures, but will be of secondary interest to most decision makers. We also demonstrate that Willan's proposed estimate of this probability is logically flawed.